Westerink Walter M A, Schoonen Willem G E J
Department of Pharmacology, NV Organon, Molenstraat 110, 5340 BH Oss, The Netherlands.
Toxicol In Vitro. 2007 Dec;21(8):1581-91. doi: 10.1016/j.tiv.2007.05.014. Epub 2007 Jun 8.
Early in vitro toxicity screening might improve the success rate of new chemical entities in pharmaceutical development. In previous studies, the advantage of cytotoxicity screening with the HepG2 cell line was shown. Cytotoxicity could be identified for 70% of the compounds in these assays as compared with known toxicity in either in vitro assays in primary hepatocytes, in in vivo assays in rats, or in (pre-)clinical development in humans. The low Phase I and II enzyme levels in HepG2 cells might have been responsible for the fact that 30% of the compounds scored negative. Therefore, we performed two follow-up studies in which Cytochrome P450 (CYP) enzymes and Phase II metabolism were examined. In the present study, the transcript levels of CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4 were measured with quantitative PCR. Results showed that transcripts of all CYPs were present in HepG2 cells, however, mRNA levels of most CYPs were dramatically lower than in primary human hepatocytes. These results were confirmed with luminometric assays which were used to measure the enzyme activities of CYP1A1, 1A2, 2C9, and 3A4. Regulation of CYP1A1, 1A2, 2B6, 2C8, 2D6, 2E1, and 3A4 by the aryl hydrocarbon receptor, pregnane X receptor and constitutive androstane receptor was studied in HepG2 cells at the mRNA and/or enzyme level. Regulation of CYP1A1, 1A2, 2B6, and 3A4 mRNA levels was similar to the regulation in primary human hepatocytes. In contrast, CYP2C8 mRNA levels are inducible in primary human hepatocytes, but not in HepG2 cells, after treatment with PXR/CAR activators. Consistent with other studies, CYP2D6 and 2E1 transcript levels were not changed after treatment with AhR, PXR, and CAR activators. Moreover, CYP1A1 and 1A2 enzyme levels could be induced by AhR agonists and CYP3A4 by PXR agonists. As a consequence of the low levels of CYPs in HepG2 cells, cytotoxicity of several compounds might have been missed or underestimated as compared with cytotoxicity in primary human hepatocytes. Inducing HepG2 cells with particular receptor stimulators might lead to higher toxicity for several of the tested compounds. Compared to primary human hepatocytes, HepG2 cells are a relatively easy-to-handle tool to study the up-regulation of CYP1A1, 1A2, 2B6, and 3A4.
早期体外毒性筛选可能会提高药物研发中新化学实体的成功率。在先前的研究中,已显示出使用HepG2细胞系进行细胞毒性筛选的优势。与原代肝细胞中的体外试验、大鼠体内试验或人类(临床前)临床开发中的已知毒性相比,在这些试验中70%的化合物可鉴定出细胞毒性。HepG2细胞中I相和II相酶水平较低可能是30%的化合物检测结果为阴性的原因。因此,我们进行了两项后续研究,检测了细胞色素P450(CYP)酶和II相代谢。在本研究中,采用定量PCR检测CYP1A1、1A2、2A6、2B6、2C8、2C9、2C19、2D6、2E1和3A4的转录水平。结果显示,所有CYP转录本均存在于HepG2细胞中,然而,大多数CYP的mRNA水平显著低于原代人肝细胞。这些结果通过用于检测CYP1A1、1A2、2C9和3A4酶活性的发光测定法得到证实。在HepG2细胞中,在mRNA和/或酶水平上研究了芳烃受体、孕烷X受体和组成型雄甾烷受体对CYP1A1、1A2、2B6、2C8、2D6、2E1和3A4的调控。CYP1A1、1A2、2B6和3A4 mRNA水平的调控与原代人肝细胞中的调控相似。相比之下,用PXR/CAR激活剂处理后,CYP2C8 mRNA水平在原代人肝细胞中可诱导,但在HepG2细胞中不可诱导。与其他研究一致,用AhR、PXR和CAR激活剂处理后,CYP2D6和2E1转录水平未发生变化。此外AhR激动剂可诱导CYP1A1和1A2酶水平,PXR激动剂可诱导CYP3A4酶水平。由于HepG2细胞中CYP水平较低,与原代人肝细胞中的细胞毒性相比,几种化合物的细胞毒性可能被漏检或低估。用特定受体刺激剂诱导HepG2细胞可能会使几种受试化合物产生更高的毒性。与原代人肝细胞相比,HepG2细胞是研究CYP1A1、1A2、2B6和3A4上调的相对易于操作的工具。